IMV Inc IMVIF

RE:Hmm. So, collaboration continues?

[Breakthorough]

It looks like a continuation of Spirel for clarification, including an arm without cyclophosphamide and snd arm with DPX alone. Apart, the only two positive statement (no money involved) are: 1) "Patient population and clinical endpoints aligned with FDA guidance for potential path to accelerated approval." 2) "In this collaboration we look forward to collaborating with Merck, beyond the provision of Keytruda, to ensure clinical and regulatory alignment, thus optimizing our probability of success."